This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VaxGen Slips on AIDS Trial News

Shares of VaxGen (VXGN) dropped nearly 6% Wednesday afternoon following the company's announcement that its experimental AIDS vaccine failed a clinical test in Thailand.

The Brisbane, Calif., biotechnology company said the vaccine failed both objectives of the test: prevention of HIV, the virus that causes AIDS, and slowing the progression of the disease among those who received the vaccine but later became infected with HIV.

"The outcome of this trial is one more reminder of how difficult it is to combat HIV and how important it is for the international public health community to redouble the effort to develop an effective vaccine," said Donald P. Francis, VaxGen's president. "Although we are disappointed with the outcome, VaxGen and our Thai collaborators have created a model that can be used around the world for advanced clinical research of an HIV vaccine."

During the trial, 105 volunteers who received a placebo became infected with HIV; 106 volunteers who received at least one injection of AIDSVAX B/E became infected, the company said. The trial was conducted at 17 clinical sites in the greater Bangkok area. The company said the volunteers received education and counseling every six months "to avoid behavior that could lead to HIV infection." The volunteers also were advised to assume that they may have received a placebo or that the vaccine might not be effective, the company said.

In recent trading, VaxGen was off 55 cents, or 5.6%, at $9.30 a share.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs